drugset / Trial / NCT00882518
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Chlorpromazine | Small molecule | 300 mg | Oral |
| Comparator | Chlorpromazine | Small molecule | 400 mg | Oral |
| Comparator | Chlorpromazine | Small molecule | 500 mg | Oral |
| Comparator | Chlorpromazine | Small molecule | 600 mg | Oral |
| Subject | Quetiapine | Small molecule | 400 mg | Oral |
| Subject | Quetiapine | Small molecule | 600 mg | Oral |
| Subject | Quetiapine | Small molecule | 800 mg | Oral |